NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
06. Dezember 2024 16:03 ET
|
NurExone Biologic Inc
NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)